UNI-EN 105:current report 105 uved za vlivane s BRS ENG
Firma: SOPHARMA ADSpis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
| | UNI - EN REPORT No | 105 | / | 2012 | | ||||||
| Date of issue: | 2012-10-30 | ||||||||||
| Short name of the issuer | |||||||||||
| SOPHARMA AD | |||||||||||
| Subject | |||||||||||
| current report 105 uved za vlivane s BRS ENG | |||||||||||
| Official market - legal basis | |||||||||||
| Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| The Board of Directors of Sopharma AD (the “Company") hereby notifies that on 29 October 2012 was signed a merger agreement between Sopharma AD and Bulgarian Rose – Sevtopolis AD. The agreement settles both the technical process of the merger of Bulgarian Rose – Sevtopolis AD into Sopharma AD, as well as the ensuing consequences for the two companies. The contract and the accompanying documentation have been submitted to the Financial Supervision Commission. | |||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| current report 105 uved za vlivane s BRS ENG.doc current report 105 uved za vlivane s BRS ENG.doc | current report 105 uved za vlivane s BRS ENG | ||||||||||
| SOPHARMA AD | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| SOPHARMA AD | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) | ||||||||||||
| 1220 | Sofia | ||||||||||||
| (post code) | (city) | ||||||||||||
| IlienskoShosse | 16 | ||||||||||||
| (street) | (number) | ||||||||||||
| +359 2 813 42 00 | +359 2 936 02 86 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nd | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2012-10-30 | Ognian Donev | Executive director | |||
Cena akcji Sopharma
Cena akcji Sopharma w momencie publikacji komunikatu to None PLN. Sprawdź ile kosztuje akcja Sopharma aktualnie.
W tej sekcji znajdziesz wszystkie komunikaty ESPI EBI Sopharma.
